Business Description
NexImmune Inc
NAICS : 541713
SIC : 2834
ISIN : US65344D2080
Share Class Description:
NEXI: Ordinary SharesDescription
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 67.33 | |||||
| Equity-to-Asset | 0.41 | |||||
| Debt-to-Equity | 0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 5.1 | |||||
| 3-Year EPS without NRI Growth Rate | 6.8 | |||||
| 3-Year FCF Growth Rate | 4.5 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.07 | |||||
| 9-Day RSI | 44.01 | |||||
| 14-Day RSI | 40.35 | |||||
| 6-1 Month Momentum % | 53.57 | |||||
| 12-1 Month Momentum % | -49.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.06 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.5 | |||||
| Shareholder Yield % | 13.91 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -191.06 | |||||
| ROA % | -134.37 | |||||
| ROIC % | -628.98 | |||||
| ROC (Joel Greenblatt) % | -775.66 | |||||
| ROCE % | -188.4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.03 | |||||
| Price-to-Tangible-Book | 1.05 | |||||
| Price-to-Net-Current-Asset-Value | 11.53 | |||||
| FCF Yield % | -679.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NEXI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NexImmune Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -30.89 | ||
| Beta | 2.2 | ||
| Volatility % | 599.6 | ||
| 14-Day RSI | 40.35 | ||
| 14-Day ATR ($) | 0.379648 | ||
| 20-Day SMA ($) | 3.41875 | ||
| 12-1 Month Momentum % | -49.04 | ||
| 52-Week Range ($) | 1.2501 - 28.6949 | ||
| Shares Outstanding (Mil) | 1.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NexImmune Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NexImmune Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NexImmune Inc Frequently Asked Questions
What is NexImmune Inc(NEXI)'s stock price today?
The current price of NEXI is $3.46. The 52 week high of NEXI is $28.69 and 52 week low is $1.25.
When is next earnings date of NexImmune Inc(NEXI)?
The next earnings date of NexImmune Inc(NEXI) is 2024-05-10 Est..
Does NexImmune Inc(NEXI) pay dividends? If so, how much?
NexImmune Inc(NEXI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers